CytoImmune Therapeutics, Inc.
CytoImmune Therapeutics is a clinical-stage biotechnology company focused on developing innovative cell therapy solutions for cancer. They specialize in off-the-shelf natural killer (NK) cell therapies, leveraging proprietary engineering platforms to target solid tumors and hematologic malignancies. Their mission is to create safe, effective, and accessible immunotherapies to improve patient outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
CytoImmune Therapeutics, Inc.
Monrovia, California, United States, North America
Products
Clinical‑stage engineered NK cell therapy targeting PD-L1 for non‑small cell lung cancer (NSCLC)
An allogeneic, engineered NK cell program that targets PD-L1 and is designed to secrete IL-15 and a bispecific engager to provide direct tumor targeting and stimulation of innate and adaptive immunity; advanced to Phase I clinical testing (first patient dosed reported).
Engineered NK cell program targeting FLT3 for hematologic malignancy (AML)
A development-stage engineered NK cell program targeting FLT3 for acute myeloid leukemia, described in pipeline materials with planned IND activities.
Clinical‑stage engineered NK cell therapy targeting PD-L1 for non‑small cell lung cancer (NSCLC)
An allogeneic, engineered NK cell program that targets PD-L1 and is designed to secrete IL-15 and a bispecific engager to provide direct tumor targeting and stimulation of innate and adaptive immunity; advanced to Phase I clinical testing (first patient dosed reported).
Engineered NK cell program targeting FLT3 for hematologic malignancy (AML)
A development-stage engineered NK cell program targeting FLT3 for acute myeloid leukemia, described in pipeline materials with planned IND activities.
Services
Development and manufacturing services for cell therapies
Contract or partner-focused development and GMP manufacturing services for engineered cell therapy products, including process development, CMC support and clinical manufacturing capacity.
Development and manufacturing services for cell therapies
Contract or partner-focused development and GMP manufacturing services for engineered cell therapy products, including process development, CMC support and clinical manufacturing capacity.
Expertise Areas
- Engineered NK cell therapy development
- Allogeneic cell therapy manufacturing and CMC
- Preclinical pharmacology and IND-enabling studies
- Early‑phase clinical trial execution
Key Technologies
- CAR-engineered natural killer (NK) cells
- Soluble IL-15 secretion by cell therapy products
- Bispecific NK-engager (BiKE) secretion
- Feeder cell expansion using membrane-bound cytokines and co-stimulatory ligands